Drugmakers Pfizer (PFE) - Get Report and Moderna (MRNA) - Get Report reportedly declined to form an alliance with Johnson & Johnson (JNJ) - Get Report to address concerns about a rare blood-clotting disorder among recipients of coronavirus vaccines, according to a media report.
Pfizer and Moderna executives declined the offer and said "their vaccines appeared safe," people familiar with the matter told the Journal. AstraZeneca agreed to work with J&J, the Journal reported.
Six women who received J&J’s vaccine developed blood clots and one died, out of more than seven million doses administered across the U.S., according to federal health officials, the Journal reported.
On Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration urged suspension of the use of J&J's coronavirus vaccine amid concern about the blood-clotting issue.
J&J, the New Brunswick, N.J., health-care group, believes collaborative scientific exchange can help answer questions about patient safety, a company spokesman told the Journal.
Over 198.3 million doses of coronavirus vaccines have been administered in the U.S. according to data from the Centers for Disease Control and Prevention.
Early this month reports suggested that millions of doses of J&J's vaccine were ruined by an ingredient mixup at Emergent Biosolutions (EBS) - Get Report, one of Johnson & Johnson's supply-chain partners.
At last check shares of J&J rose 0.3% to $160.88.